全身性硬化症における標的治療:臨床試験における新薬の記述的レビュー

Morgan Emokpae¹, Crystal Cheung, Manvitha Nadella

¹Yale School of Medicine, Department of Internal Medicine, Section of Rheumatology, Allergy & Immunology, New Haven, Connecticut, USA.

Current opinion in rheumatology

|August 20, 2025

まとめ

組織性硬化症 (SSc) の治療は困難です. 生物学的薬や小分子を含む新しい標的型療法が重要な疾患メカニズムを調節し患者の治療結果を改善する見込みを示しています

科学分野:

リウマトロジ
免疫学
薬理学について

背景:

組織性硬化症 (Systemic Sclerosis,SSc) は治療において大きな課題を提示しています.
従来の免疫抑制薬は,SScにおいて限られた疾患修正効果を発揮する.
比較試験の欠如は,免疫抑制薬と抗線維薬の間の治療選択を妨げています.

研究の目的:

SScの標的治療における最近の進歩をレビューする.
重要なSScメカニズムを標的とした新生物と小分子に焦点を当てます.
SScの治療戦略の最新情報を提供してください.

主な方法:

2020年1月から2025年4月の臨床試験の文献検索.
検索したデータベース:PubMed/MEDLINE,clinicaltrials.gov,euclinicaltrials.eu
14件の選択研究 (試験,概要,ケースシリーズ) の詳細な分析

主要な成果:

分子プロファイリングは,SScの異なる炎症性および線維性エンドタイプを特定します.
画像検査では標的治療に適した線維炎症のサブセットが示されています
新興の標的型療法により,SScに対する新たな治療法が提供される可能性があります.

結論:

SScにおける最近の臨床試験は,患者の改善への希望を示しています.
SScのエンドタイプに関する理解の進歩は,標的治療の開発を導く.
将来の研究は,SSc治療の患者特有のガイドラインに焦点を当てるべきです.

キーワード:

レイノ現象肺繊維症スクレロダーマ腎臓発作皮膚繊維症組織性硬化症標的型療法トリートメント

さらに関連する動画

12:27

A Pipeline to Investigate the Structures and Signaling Pathways of Sphingosine 1-Phosphate Receptors

Published on: June 8, 2022

3.5K

04:47

Author Spotlight: Evaluating Traditional Chinese Therapy for Ankylosing Spondylitis in Mice

Published on: October 27, 2023

1.2K

関連する概念動画

02:57

Targeted Cancer Therapies

7.8K

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

7.8K

01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

453

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...

453

01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

231

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...

231

01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

267

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...

267

01:26

Targets for Drug Action: Overview

7.4K

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...

7.4K

01:29

Drugs for Treatment of Ulcerative Colitis in IBD

236

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...

236

関連する実験動画